糖尿病及其药物是否是 COVID-19 发展的危险因素？西西里岛一项基于人群的研究数据。
Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily.
机构信息
Experimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Italy.
Experimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Italy.
出版信息
Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):396-398. doi: 10.1016/j.numecd.2020.09.028. Epub 2020 Oct 1.
Abstract
BACKGROUND AND AIMS
Diabetes mellitus (DM) has been associated with higher incidence of severe cases of COVID-19 in hospitalized patients, but it is unknown whether DM is a risk factor for the overall COVID-19 incidence. The aim of present study was to investigate whether there is an association of DM with COVID-19 prevalence and case fatality, and between different DM medications and risk for COVID-19 infection and death.
METHODS AND RESULTS
retrospective observational study on all SARS-CoV-2 positive (SARS-CoV-2) cases and deaths in Sicily up to 2020, May 14th. No difference in COVID-19 prevalence was found between people with and without DM (RR 0.92 [0.79-1.09]). Case fatality was significantly higher in SARS-CoV-2 with DM (RR 4.5 [3.55-5.71]). No diabetes medication was associated with differences in risk for SARS-Cov2 infection.
CONCLUSIONS
in Sicily, DM was not a risk factor for COVID-19 infection, whereas it was associated with a higher case fatality.
摘要
背景与目的
糖尿病（DM）与住院患者中 COVID-19 重症病例的发生率增加有关，但 DM 是否是 COVID-19 总发病率的危险因素尚不清楚。本研究旨在探讨 DM 是否与 COVID-19 患病率和病死率有关，以及不同的 DM 药物与 COVID-19 感染和死亡的风险之间是否存在关联。
方法和结果
这是一项针对西西里岛截至 2020 年 5 月 14 日所有 SARS-CoV-2 阳性（SARS-CoV-2）病例和死亡的回顾性观察性研究。患有和不患有 DM 的人 COVID-19 患病率没有差异（RR 0.92 [0.79-1.09]）。SARS-CoV-2 合并 DM 的病死率显著更高（RR 4.5 [3.55-5.71]）。没有糖尿病药物与 SARS-Cov2 感染的风险差异相关。
结论
在西西里岛，DM 不是 COVID-19 感染的危险因素，而是与更高的病死率相关。
相似文献
1
Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily.糖尿病及其药物是否是 COVID-19 发展的危险因素？西西里岛一项基于人群的研究数据。
Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):396-398. doi: 10.1016/j.numecd.2020.09.028. Epub 2020 Oct 1.
2
[Can diabetes and its related hypoglycemic drug treatment be considered risk factors for health outcomes in COVID-19 patients? The results of a study in the population residing in Sicily Region (Southern Italy)].糖尿病及其相关降糖药物治疗能否被视为新冠病毒肺炎患者健康结局的危险因素？一项针对意大利南部西西里岛地区居民的研究结果
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):315-322. doi: 10.19191/EP20.5-6.S2.132.
3
Estimation of case-fatality rate in COVID-19 patients with hypertension and diabetes mellitus in the New York state: a preliminary report.纽约州 COVID-19 合并高血压和糖尿病患者病死率的评估：初步报告。
Epidemiol Infect. 2021 Jan 8;149:e14. doi: 10.1017/S0950268821000066.
4
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study.沙特阿拉伯住院患者中的糖尿病和新冠病毒-19：一项单中心回顾性研究。
Cardiovasc Diabetol. 2020 Dec 5;19(1):205. doi: 10.1186/s12933-020-01184-4.
5
Prevalence and impact of diabetes and cardiovascular disease on clinical outcome among patients with COVID-19 in Bangladesh.糖尿病和心血管疾病在孟加拉国新冠肺炎患者中的患病率及其对临床结局的影响。
Diabetes Metab Syndr. 2021 May-Jun;15(3):1009-1016. doi: 10.1016/j.dsx.2021.05.005. Epub 2021 May 8.
6
Patients with prediabetes are at greater risk of developing diabetes 5 months postacute SARS-CoV-2 infection: a retrospective cohort study.患有前驱糖尿病的患者在急性 SARS-CoV-2 感染后 5 个月发生糖尿病的风险更高：一项回顾性队列研究。
BMJ Open Diabetes Res Care. 2023 Jun;11(3). doi: 10.1136/bmjdrc-2022-003257.
7
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea.韩国大邱市 2019 年冠状病毒病中度至重度感染合并糖尿病患者的临床特征和结局。
Diabetes Metab J. 2020 Aug;44(4):602-613. doi: 10.4093/dmj.2020.0146. Epub 2020 Aug 12.
8
Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients.糖尿病以依赖海拔的方式增加 COVID-19 的风险：对 1280806 名墨西哥患者的分析。
PLoS One. 2021 Aug 3;16(8):e0255144. doi: 10.1371/journal.pone.0255144. eCollection 2021.
9
Sex differences in the incidence, mortality, and fatality of COVID-19 in Peru.秘鲁新冠肺炎发病率、死亡率及病死率的性别差异。
PLoS One. 2021 Jun 14;16(6):e0253193. doi: 10.1371/journal.pone.0253193. eCollection 2021.
10
COVID-19 and Undiagnosed Pre-diabetes or Diabetes Mellitus Among International Migrant Workers in Singapore.新加坡国际移民工人中的 COVID-19 和未确诊的糖尿病前期或糖尿病。
Front Public Health. 2020 Nov 11;8:584249. doi: 10.3389/fpubh.2020.584249. eCollection 2020.
引用本文的文献
1
SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-Analysis, and Bayesian Sensitivity Assessment.SGLT2抑制剂在COVID-19中的应用：伞状综述、荟萃分析和贝叶斯敏感性评估。
Diseases. 2025 Feb 21;13(3):67. doi: 10.3390/diseases13030067.
2
Is Metformin Use Associated with a More Favorable COVID-19 Course in People with Diabetes?二甲双胍的使用是否与糖尿病患者更有利的COVID-19病程相关？
J Clin Med. 2024 Mar 24;13(7):1874. doi: 10.3390/jcm13071874.
3
Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy.2 型糖尿病合并心肌病患者的抗糖尿病药物与 COVID-19 结局的关系。
Sci Rep. 2024 Mar 27;14(1):7227. doi: 10.1038/s41598-024-57871-9.
4
Stress Hyperglycemia, Diabetes Mellitus and COVID-19 Infection: Risk Factors, Clinical Outcomes and Post-Discharge Implications.应激性高血糖、糖尿病与新型冠状病毒肺炎感染：危险因素、临床结局及出院后影响
Front Clin Diabetes Healthc. 2022 Apr 7;3:826006. doi: 10.3389/fcdhc.2022.826006. eCollection 2022.
5
Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.糖尿病合并 COVID-19 患者的非胰岛素类降糖药物：系统评价和荟萃分析。
J Diabetes. 2023 Feb;15(2):86-96. doi: 10.1111/1753-0407.13359. Epub 2023 Jan 23.
6
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.预用钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT-2i）可能显著改善糖尿病患者的新冠病毒感染结局：系统评价、荟萃分析和荟萃回归。
Diabetes Res Clin Pract. 2023 Jan;195:110205. doi: 10.1016/j.diabres.2022.110205. Epub 2022 Dec 9.
7
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control.用于治疗新冠肺炎的二肽基肽酶4抑制剂：超越血糖控制。
World J Virol. 2022 Nov 25;11(6):399-410. doi: 10.5501/wjv.v11.i6.399.
8
Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis.降糖药物与 COVID-19 住院前糖尿病患者结局的关联：系统评价和网络荟萃分析。
JAMA Netw Open. 2022 Dec 1;5(12):e2244652. doi: 10.1001/jamanetworkopen.2022.44652.
9
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.抗糖尿病治疗对 2 型糖尿病合并 COVID-19 患者临床结局的影响：系统评价和荟萃分析。
Ann Pharmacother. 2023 Jul;57(7):776-786. doi: 10.1177/10600280221133577. Epub 2022 Oct 29.
10
Analysis of Perception, Reasons, and Motivations for COVID-19 Vaccination in People with Diabetes across Sub-Saharan Africa: A Mixed-Method Approach.撒哈拉以南非洲地区糖尿病患者对 COVID-19 疫苗接种的认知、原因和动机的分析：混合方法研究。
Int J Environ Res Public Health. 2022 Jun 27;19(13):7875. doi: 10.3390/ijerph19137875.
本文引用的文献
1
Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies.糖尿病是 COVID-19 病情加重和住院死亡的危险因素：观察性研究的荟萃分析。
Nutr Metab Cardiovasc Dis. 2020 Jul 24;30(8):1236-1248. doi: 10.1016/j.numecd.2020.05.014. Epub 2020 May 29.
2
New-Onset Diabetes in Covid-19.新冠病毒感染引发的新发糖尿病
N Engl J Med. 2020 Aug 20;383(8):789-790. doi: 10.1056/NEJMc2018688. Epub 2020 Jun 12.
3
Clinical Characteristics of Hospitalized Individuals Dying With COVID-19 by Age Group in Italy.意大利按年龄组划分的因 COVID-19 住院死亡个体的临床特征。
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1796-1800. doi: 10.1093/gerona/glaa146.
4
Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study.二肽基肽酶-4 抑制剂与 COVID-19 在 2 型糖尿病患者中的暴露情况：一项病例对照研究。
Diabetes Obes Metab. 2020 Oct;22(10):1946-1950. doi: 10.1111/dom.14097. Epub 2020 Jul 1.
5
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
6
Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.2019冠状病毒病中的糖尿病：患病率、病理生理学、预后及实际考量
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):303-310. doi: 10.1016/j.dsx.2020.04.004. Epub 2020 Apr 9.
7
COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used).意大利糖尿病患者的新冠肺炎感染情况：对我们未来的启示（一次可供借鉴的经验）
Diabetes Res Clin Pract. 2020 Apr;162:108137. doi: 10.1016/j.diabres.2020.108137. Epub 2020 Apr 4.
8
COVID-19 and diabetes: Can DPP4 inhibition play a role?2019冠状病毒病与糖尿病：二肽基肽酶4抑制作用能否发挥作用？
Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26.
9
Prevalence and impact of diabetes among people infected with SARS-CoV-2.2019冠状病毒病感染者中糖尿病的患病率及影响
J Endocrinol Invest. 2020 Jun;43(6):867-869. doi: 10.1007/s40618-020-01236-2. Epub 2020 Mar 28.
10
Covid-19: risk factors for severe disease and death.新冠病毒病：重症和死亡的风险因素
BMJ. 2020 Mar 26;368:m1198. doi: 10.1136/bmj.m1198.
Zotero 插件